As Pony AI Inc. slashes hardware costs by 70% and plans a major fleet expansion, investors are weighing its potential as a high-stakes bet on the future of self-driving cars in key Asian markets.
Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
Defense contractor L3Harris Technologies has been awarded a U.S. Navy contract to advance the Marine Corps' precision-strike capabilities with its long-range Red Wolf missile system, designed to counter maritime threats in the Pacific.
New industry data reveals fashion's climate progress has stalled, with coal reliance remaining high and renewable energy adoption minimal. As the easy wins fade, experts call for targeted investment and collective action to tackle the sector's most polluting facilities.
Bank of America has revised its price target for consumer goods giant Kimberly-Clark downward, citing sector-wide valuation pressures, even as the company reports resilient earnings and advances its transformation into a broader health and wellness player.
The Trump administration has escalated pressure on Cuba by declaring a national emergency and threatening punitive tariffs on countries supplying it with oil, while simultaneously finalizing a reciprocal trade agreement with Guatemala aimed at bolstering Western Hemisphere supply chains.
The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.
LVMH's recent 0.8% single-day gain to €546.9 offers a glimmer of hope after a period of weaker performance, sparking debate among analysts over whether the market is underestimating the luxury conglomerate's long-term resilience and global footprint.
Seaport Research has lowered its price target for Polaris Inc. (PII) following a strong fourth quarter overshadowed by softer-than-expected forward guidance. The firm maintains a Buy rating, citing the company's market share gains and operational improvements amidst ongoing tariff challenges.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Morgan Stanley reaffirms its Overweight rating on NIO Inc., maintaining a $7 price target. Analyst Tim Hsiao highlights the EV maker's plan for 40-50% annual delivery growth through 2026 and improved strategic focus following a meeting with founder William Li.
The global lifestyle retailer MINISO continues its aggressive capital return strategy, repurchasing millions of shares under a Rule 10b5-1 program as analysts remain bullish on the stock's outlook.
Soybean prices extended their decline on Friday, pressured by lackluster export sales data and a broader commodity sell-off. With key commitments lagging last year's pace, traders are now looking ahead to next week's crush data for signs of domestic demand strength.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
While the small-cap index is a hunting ground for growth, some constituents face significant headwinds. We examine three companies where valuation and market dynamics warrant a cautious approach.
A strategic report warns that recent tariff hikes could significantly increase clothing costs for American shoppers unless brands rapidly diversify production to a network of partner nations.
Secretary-General António Guterres warns the United Nations could exhaust its regular budget cash by July, citing chronic non-payment of dues by member states and a "Kafkaesque" financial cycle that threatens its core operations.
TAL Education Group's stock soared following robust Q3 FY2026 results and a new share repurchase program, marking a potential inflection point for the Chinese tutoring giant navigating a post-regulatory landscape. Analysts debate if the rally signals a lasting recovery or a temporary reprieve.
LVMH's wine and spirits arm, led by Hennessy, faces a sharp profit decline amid weak U.S. and Chinese demand, while Rémy Cointreau reports a modest rebound in Cognac sales, highlighting a divided market outlook.
Despite a challenging year that saw Nike's shares fall sharply, a majority of analysts maintain a cautiously optimistic outlook, betting on the sportswear giant's long-term brand strength and innovation pipeline to fuel a recovery.
